Branch, Iowa, also known as the Aspelmeier Family; to retain control of Mediapolis Bancorporation, Mediapolis, Iowa, and thereby indirectly acquire Mediapolis Savings Bank.

4. Donald and Carol Schmidgall, Hartzell and Marian Schmidgall, Jon and Julie Schmidgall, Ronald and Jane Schmidgall, Mediapolis, Iowa, also known as the Schmidgall Family; to retain control of Mediapolis Bancorporation, Mediapolis, Iowa, and thereby indirectly acquire Mediapolis Savings Bank, Mediapolis, Iowa.

Board of Governors of the Federal Reserve System, November 14, 2003.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 03–28940 Filed 11–19–03; 8:45 am]

BILLING CODE 6210–01–S

GENERAL SERVICES ADMINISTRATION

Office of Governmentwide Policy; Revision of the Standard Form 1103

AGENCY: Office of Governmentwide Policy, GSA.

ACTION: Notice.

SUMMARY: The General Services Administration, Office of Governmentwide Policy revised Standard Form 1103, U.S. Government Bill of Lading to reflect the new regulation on transportation payments and audits. This form is now used only for overseas and international shipments. All other shipments follow the procedures in 41 CFR 102–118.

SF 1103 (which new title is U.S. Government Bill of Lading—International and Domestic Overseas Shipments) is authorized for local reproduction. You can obtain the updated camera copy in two ways:

On the Internet. Address: *http://w3.gsa.gov//web/c/newform.nsf/MainMenu?OpenForm,* or;

From GSA, Forms Management, Attn.: Barbara Williams, (202) 501–0581.

FOR FURTHER INFORMATION CONTACT: Ms. Barbara Williams, General Services Administration, (202) 501–0581 for availability of the form and Ed Davis, General Services Administration (202) 208–7638 for any other information.

DATES: Effective November 20, 2003.

Dated: November 5, 2003.

Barbara M. Williams,

Deputy Standard and Optional Forms Management Officer, General Services Administration.

[FR Doc. 03–28939 Filed 11–19–03; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003D–0229]

Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry on Continuous Marketing Applications: Pilot 2—Scientific Feedback and Interactions During Development of Fast Track Products Under the Prescription Drug User Fee Act

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection contained in the guidance for industry on Continuous Marketing Applications: Pilot 2—Scientific Feedback and Interactions During Development of Fast Track Products Under the Prescription Drug User Fee Act of 1992 (PDUFA).

DATES: Submit written or electronic comments on the collection of information by January 20, 2004.

ADDRESSES: Submit electronic comments on the collection of information to: *http://www.fda.gov/dockets/ecomments.* Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Karen Nelson, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Guidance for Industry on Continuous Marketing Applications: Pilot 2—Scientific Feedback and Interactions During Development of Fast Track Products Under the Prescription Drug User Fee Act (OMB Control Number 0910–0518)

FDA is requesting OMB approval under the PRA (44 U.S.C. 3507) for the reporting and recordkeeping requirements contained in the guidance for industry entitled ''Continuous Marketing Applications: Pilot 2—Scientific Feedback and Interactions During Development of Fast Track Products Under Prescription Drug User Fee Act.'' This guidance discusses how the agency will implement a pilot program for frequent scientific feedback and interactions between FDA and applicants during the investigational phase of the development of certain Fast Track drug and biological products. Applicants are being asked to apply to participate in the pilot 2 program.

In conjunction with the June 2002 reauthorization of the PDUFA, FDA agreed to meet specific performance goals (PDUFA goals). The PDUFA goals include two pilot programs to explore the continuous marketing application